Market Overview

Baird Remains Buyers Of Gilead Before Earnings Release

Related GILD
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers
North Tide Capital, Llc Buys Impax Laboratories, Allergan PLC, Accuray, Sells Community Health ... (GuruFocus)
2 Dividend Aristocrats Trading At A Discount
President Trump Doubles Down On Healthcare Criticism, Says Drug Prices Are 'Astronomical'
Procter & Gamble: Gillette Might Be For Sale (Seeking Alpha)

In a report Thursday morning, analysts at Baird stated that they remain buyers of Gilead Sciences, Inc. (NASDAQ: GILD) before the company's fourth quarter earnings call next Tuesday, February 3.

Investors have been concerned that Gilead might disappoint after pricing concerns in the Hep C market.

"We expect Gilead's HCV franchise to return to form to close out 2014 after approval of Harvoni early on in the quarter has reversed the secondary warehousing effect of HCV patients. Our prescription trend analysis throughout the quarter indicates Sovaldi and Harvoni sales in the U.S. alone of $1.2B and $2.0B, respectively," they wrote.

The analysts also expect a major topic of discussion will be HCV pricing competition between AbbVie (NYSE: ABBV) and Express Scripts (NASDAQ: ESRX).

They stated: "We don't expect to get definitive read-through on the actual magnitude of discounts until next quarter's update but we believe Gilead's discount is likely trending towards 25%."

The consensus fourth quarter EPS estimate is expected to be $2.17, however Baird analysts estimate $2.28 EPS.

If the fourth quarter EPS comes in at $2.28, that would put Gilead at $7.90 EPS for 2014.

The firm rates Gilead at an Outperform and has a $126 price target.

Latest Ratings for GILD

Feb 2017CitigroupDowngradesBuyNeutral
Nov 2016Stifel NicolausInitiates Coverage OnBuy
Nov 2016MizuhoInitiates Coverage OnBuy

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Analyst Color Long Ideas FDA Analyst Ratings Trading Ideas


Related Articles (ESRX + ABBV)

View Comments and Join the Discussion!